Race Oncology is a specialty pharmaceutical company focused on rediscovering and rescuing life-saving drugs that can deliver early commercial milestones. Race Oncology’s first asset is Bisantrene, a small molecule Chemotherapy drug that has been evaluated clinically for Acute Myeloid Leukaemia (AML).
|10/03/2020||Race further strengthens Clinical Advisory Board||Download|
|06/03/2020||Race Secures A$1.8m strategic placement||Download|
|06/03/2020||Proposed issue of Securities - RAC||Download|
|06/03/2020||Dr John Cullity appointed Non-Executive Chairman||Download|
|02/03/2020||Appendix 3Y-Dr Daniel Tillett||Download|
|25/02/2020||Appendix 4D & Half-Year Financial Statements||Download|
|20/02/2020||Race significantly strengthens Clinical Advisory Board||Download|